Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/5794
Title: In vitro and in vivo experimental models for drug screening and development for Chagas disease
Authors: Romanha, Álvaro José
Castro, Solange Lisboa de
Soeiro, Maria de Nazaré Correia
Vieira, Joseli Lannes
Ribeiro, Isabela
Talvani, André
Bourdin, Bernadette
Blum, Bethania
Olivieri, Bianca
Zani, Carlos Leomar
Spadafora, Carmenza
Chiari, Égler
Chatelain, Eric
Chaves, Gabriela
Calzada, José Eduardo
Bustamante, Juan Manuel
Freitas Junior, Lucio Holanda Gondim de
Romero, Luz I.
Bahia, Maria Terezinha
Lotrowska, Michel
Soares, Milena Botelho Pereira
Andrade, Sonia Gumes
Armstrong, Tanya
Degrave, Wim
Andrade, Zilton de Araújo
Affilliation: Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil/Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Drugs for Neglected Disease Initiative.Geneva, Switzerland
Universidade Federal de Ouro Preto. Departamento de Ciências Biológicas. Ouro Preto, MG, Brasil.
Drugs for Neglected Disease Initiative. Geneva, Switzerland.
Drugs for Neglected Disease Initiative, Geneva, Switzerland.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Belo Horizonte, MG, Brasil.
Instituto de Investigaciones Científicas y Servicios de Alta Tecnologia- AIP. Clayton, Panamá.
Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brasil.
Drugs for Neglected Disease Initiative.Geneva, Switzerland
Médecins sans Frontières. Geneva, Switzerland.
Instituto Conmemorativo Gorgas de Estudios de la Salud. Panamá, Panamá.
University of Georgia. Center for Tropical and Emerging Global Disease. GA, USA..
Institute Pasteur-Korea. Center for Neglected Diseases Drug Discovery. Gyeonggi-do, Korea.
Instituto de Investigaciones Científicas y Servicios de Alta Tecnologia-AIP. Clayton, Panamá.
Universidade Federal de Ouro Preto. Departamento de Ciências Biológicas. Ouro Preto, MG, Brasil.
Drugs for Neglected Disease Initiative. Geneva, Switzerland.
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.
Murdoch University. Murdoch, Austrália
Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil / Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.
Abstract: Chagas disease, a neglected illness, affects nearly 12-14 million people in endemic areas of Latin America. Al¬though the occurrence of acute cases sharply has declined due to Southern Cone Initiative efforts to control vector transmission, there still remain serious challenges, including the maintenance of sustainable public policies for Chagas disease control and the urgent need for better drugs to treat chagasic patients. Since the introduction of benznidazole and nifurtimox approximately 40 years ago, many natural and synthetic compounds have been as¬sayed against Trypanosoma cruzi, yet only a few compounds have advanced to clinical trials. This reflects, at least in part, the lack of consensus regarding appropriate in vitro and in vivo screening protocols as well as the lack of biomarkers for treating parasitaemia. The development of more effective drugs requires (i) the identification and validation of parasite targets, (ii) compounds to be screened against the targets or the whole parasite and (iii) a panel of minimum standardised procedures to advance leading compounds to clinical trials. This third aim was the topic of the workshop entitled Experimental Models in Drug Screening and Development for Chagas Disease, held in Rio de Janeiro, Brazil, on the 25th and 26th of November 2008 by the Fiocruz Program for Research and Technological Development on Chagas Disease and Drugs for Neglected Diseases Initiative. During the meeting, the minimum steps, requirements and decision gates for the determination of the efficacy of novel drugs for T. cruzi control were evaluated by interdisciplinary experts and an in vitro and in vivo flowchart was designed to serve as a general and standardised protocol for screening potential drugs for the treatment of Chagas disease.
Keywords: Trypanosoma cruzi
Chagas disease treatment
drug screening
benznidazole
Issue Date: 2010
Publisher: Instituto Oswaldo Cruz
Citation: ROMANHA, Alvaro et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 105(2): 233-238, March 2010
ISSN: 0074-0276
Copyright: open access
Appears in Collections:IOC - Artigos de Periódicos
BA - IGM - Artigos de Periódicos
MG - IRR - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
100.2010.pdf613.6 kBAdobe PDFThumbnail
View/Open



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.